2021年6月16日 · A combination of antibodies called casirivimab and imdevimab, produced by Regeneron, did not lower mortality when all patients in the study were taken together, investigators of the United Kingdom's Recovery trial announced today—but it reduced deaths by one-fifth among those who did not produce antibodies themselves.

Receiving REGEN-COV may benefit certain people with COVID-19 and may help prevent certain people who have been exposed to someone who is infected with SARS-CoV-2 from getting SARS-CoV-2 infection,...

We systematically assessed beneficial and harmful effects of monoclonal antibodies for coronavirus disease 2019 (COVID-19) treatment, and prophylaxis in individuals exposed to severe acute respiratory syndrome coronavirus 2.

• Allergic reactions. Allergic reactions can happen during and after infusion with casirivimab and imdevimab. Tell your healthcare provider or nurse, or get medical help right away if you get any

2024年12月23日 · REGEN-COV is not authorized for pre-exposure prophylaxis to prevent COVID-19 before being exposed to the SARS-CoV-2 virus -- only after exposure to the virus. Health care providers should review...

2024年4月29日 · Infusion-related reactions, occurring during the infusion and up to 24 hours after the infusion, have been observed with administration of REGEN-COV. These reactions may be severe or life threatening. Signs and symptoms of infusion related reactions may include:

new or worsening symptoms after infusion, including fever, difficulty breathing, rapid or slow heart rate, tiredness, weakness or confusion. If these occur, contact your healthcare provider or seek immediate medical attention as some of these events have required hospitalization. It is unknown if these events are related to monoclonal antibody

2024年12月12日 · People who cannot generate an effective immune response against COVID-19 can be protected with an infusion of Regeneron's antibody therapy REGN-COV, according to new data from the UK RECOVERY...

(EUA) for REGEN-COV is no longer in effect. Regeneron voluntarily requested that FDA revoke the EUA as both Regeneron and the FDA agree it is not medically appropriate, at this time, to use REGEN-COV for the treatment of mild to moderate COVID-19 or as post-exposure prophylaxis for COVID-19 in the United States.

Infusion-related reactions, occurring during the infusion and up to 24 hours after the infusion, have been observed with administration of REGEN-COV. These reactions may be severe or life-threatening. Signs and symptoms of infusion-related reactions may include: